2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity

Journal of Medicinal Chemistry

Volumn 41, Issue 17, 1998, Pages 3276-3292

  Klutchko, Sylvester R ^a   Hamby, James M ^a   Boschelli, Diane H ^a   Wu, Zhipei ^a   Kraker, Alan J ^a   Amar, Aneesa M ^a   Hartl, Brian G ^a   Shen, Cynthia ^a   Klohs, Wayne D ^a   Steinkampf, Randall W ^a   Driscoll, Denise L ^a   Nelson, James M ^a   Elliott, William L ^a   Roberts, Billy J ^a   Stoner, Chad L ^a   Vincent, Patrick W ^a   Dykes, Donald J ^b   Panek, Robert L ^a   Lu, Gina H ^a   Major, Terry C ^a   Dahring, Tawny K ^a   Hallak, Hussein ^a   Bradford, Laura A ^a   Showalter, H D Hollis ^a   Doherty, Annette M ^a   more..

^a PFIZER INC   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2,6 DICHLOROPHENYL) 2 [4 (2 DIETHYLAMINOETHOXY)PHENYLAMINO] 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SYNTHESIS; ENZYME INHIBITION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH;

3T3 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CELL DIVISION; CISPLATIN; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; OVARIAN NEOPLASMS; PLATELET-DERIVED GROWTH FACTOR; PROTEIN-TYROSINE KINASES; PYRIMIDINONES; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 15444353988     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9802259     Document Type: Article

References (44)

1. Rozengurt, E. Growth factors and cell proliferation. Curr. Opin. Cell Biol. 1992, 4, 161-165.
2. Majesky, M. W.; Reidy, M. A.; Bowen-Pope, D. F.; Hart, C. E.; Wilcox, J. N.; Schwartz, S. M. PDGF ligand and receptor gene expression during repair of arterial injury. J. Cell Biol. 1990, 111, 2149-2158.
3. Crowley, S. T.; Ray, C. J.; Nawaz, D.; Majack, R. A.; Horwitz, L. D. Multiple growth factors are released from mechanically injured vascular smooth muscle cells. Am. J. Physiol. 1995, 269, H1641-1647.
4. Ross, R.; Raines, E. W.; Bowen-Pope, D. F. The biology of platelet-derived growth factor. Cell 1986, 46, 155-169.
5. Heldin, C. H.; Westermark, B. Platelet-derived growth factor and autocrine mechanisms of oncogenic processes. Crit. Rev. Oncol. 1991, 2, 109-124.
6. Claesson-Welsh, L. Platelet-derived growth factor receptor signals. J. Biol. Chem. 1994, 269, 32023-32026.
7. Gastl, G.; Hermann, T.; Steurer, M.; Zmija, J.; Gunsilius, E.; Unger, C.; Kraft, A. Angiogenesis as a target for tumor treatment. Oncology 1997, 54, 177-184.
8. Bolen, J. B.; Penhallow, R. C.; Burkhardt, A. L. Signal transduction by the src family of tyrosine protein kinases. In Encyclopedia of Cancer; Bertino, J., Ed.; Academic: San Diego, 1997; pp 1657-1668.
9. c-src in progressive stages of human colorectal cancer. J. Clin. Invest. 1993, 91, 53-60.
10. Twamley-Stein, G. M.; Pepperkok, R.; Ansorge, W.; Courtneidge, S. A. The src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 7696-7700.
11. Libby, P.; Schwartz, D.; Brogi, E.; Tanaka, H.; Clinton, S. K. A cascade model for restenosis: A special case of atherosclerosis progression. Circulation 1992, 86, 47-52.
12. Fry, D. W. Recent advances in tyrosine kinase inhibitors. Ann. Rep. Med. Chem. 1996, 31, 151-160.
13. Klohs, W. D.; Fry, D. W.; Kraker, A. J. Inhibitors of tyrosine kinase. Curr. Opin. Oncol. 1997, 9, 562-568.
14. Spada, A. P.; Myers, M. R. Small molecule inhibitors of tyrosine kinase activity. Expert Opin. Ther. Pat. 1995, 5, 805-817.
15. Bilder, G. E.; Rojas, C. Inhibitors of the platelet-derived growth factor receptor tyrosine kinase. J. Cardiovasc. Drug Rev. 1996, 14, 380-399.
16. Myers, M. R.; He, W.; Hulme, C. Inhibitors of tyrosine kinases involved in inflammation and autoimmune disease. Curr. Pharm. Des. 1997, 3, 473-502.
17. Traxler, P. M. Protein tyrosine kinase inhibitors in cancer treatment. Expert. Opin. Ther. Pat. 1997, 7, 571-588.
18. Showalter, H. D. H.; Kraker, A. J. Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor, and src family tyrosine kinases. Pharmacol. Ther. 1997, 76, 55-71.
19. Denny, W. A.; Rewcastle, G. W.; Bridges, A. J.; Fry, D. W.; Kraker, A. J. Structure-activity relationships for 4-anilino-quinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro. Clin. Exp. Pharmacol. Physiol. 1996, 23, 424-427.
20. Rewcastle, G. W.; Murray, D. K.; Elliott, W. L.; Fry, D. W.; Howard, C. T.; Nelson, J. M.; Roberts, B. J.; Vincent, P. W.; Showalter, H. D. H.; Winters, R. T.; Denny, W. A. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)-amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors. J. Med. Chem. 1998, 41, 742-751 and previous references therein.
21. Dahring, T. K.; Lu, G. H.; Hamby, J. M.; Batley, B. L.; Kraker, A. J.; Panek, R. L. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor. J. Pharmacol. Exp. Ther. 1997, 281, 1446-1456.
22. Hamby, J. M.; Connolly, C. J. C.; Schroeder, M. C.; Winters, R. T.; Showalter, H. D. H.; Panek, R. L.; Major, T. C.; Olsewski, B.; Ryan, M. J.; Dahring, T.; Lu, G. H.; Keiser, J.; Amar, A.; Shen, C.; Kraker, A. J.; Slintak, V.; Nelson, J. M.; Fry. D. W.; Bradford, L.; Hallak, H.; Doherty, A. M. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J. Med. Chem. 1997, 40, 2296-2303.
23. (a) A preliminary account of this work has been presented. Cf. Klutchko, S.; Hamby, J.; Boschelli, D.; Panek, R.; Lu, G.; Major, T.; Keiser, J.; Amar, A.; Shen, C.; Kraker, A.; Doherty, A. Synthesis and structure-activity relationships of a series of 2-substituted 8H-pyrido[2,3-d]pyrimidin-7-one tyrosine kinase inhibitors. Book of Abstracts. 14th International Symposium on Medicinal Chemistry; 1996, P-11.02.
24. (b) Blankley, C. J.; Boschelli, D. H.; Doherty, A. M.; Hamby, J. M.; Klutchko, S. R.; Panek, R. L. Pyrido[2,3-d]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation. U. S. Patent 5,733,914; March 31, 1998.
25. Bennett, L. R.; Blankley, C. J.; Fleming, R. W.; Smith, R. D.; Tessman, Deirdre K. Antihypertensive activity of 6-arylpyrido-[2,3-d]pyrimidin-7-amine derivatives. J. Med. Chem. 1981, 24, 382-389.
26. Davis, F. A.; Stringer, O. D.Chemistry of oxaziridines. 2. Improved synthesis of 2-sulfonyloxaziridines. J. Org. Chem. 1982, 47, 1774-1775.
27. Buchi, J.; Enezian, J.; Enezian, G., Valette, G.; Pattani, C. Synthesis and action of local anesthetics derived from procaine. Helv. Chim. Acta 1960, 43, 1971-1979.
28. Trumpp-Kallmeyer, S.; Rubin, J. R.; Humblet, C.; Hamby, J. M.; Showalter, H. D. H. Development of a Binding Model to Protein Tyrosine Kinases for Substituted Pyrido[2,3-d]pyrimidine Inhibitors. J. Med. Chem. 1998, 41, 1752-1763.
29. Panek, R. L.; Lu, G. H.; Klutchko, S. R.; Batley, B. L.; Dahring, T. K.; Hamby, J. M.; Hallak, H.; Doherty, A. M.; Keiser, J. A. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J. Pharmacol. Exp. Ther. 1997, 283, 1433-1444.
30. Kraker, A. J.; Moore, C. W.; Amar, A. M.; Shen, C. S.; Nelson, J. M.; Slintak, V.; Fry, D. W.; Lu, G.; Klutchko, S.; Hamby, J. Cytotoxicity and phosphotyrosine effects of c-src kinase inhibiton by substituted pyridopyrimdine tyrosine kinase inhibitors in human colon carcinoma cell lines. Proc. 88th Ann. Meet. Am. Assoc. Cancer Res. 1997, 38, 633.
31. Chang, J. H.; Wilson, L. K.; Moyers, J. S.; Zhang, K.; Parsons, S. J. Increased levels of p21ras-GTP and enhanced DNA synthesis accompany elevated tyrosyl phosphorylation of GAP-associated proteins, p190 and p62, in c-src overexpressors. Oncogene 1993, 8, 959-967.
32. Hansen, K.; Johnell, M.; Siegbahn, A.; Rorsman, C.; Engstroem, U.; Wernstedt, C.; Heldin, C.-H.; Roennstrand, L. Mutation of a Src phosphorylation site in the PDGF β-receptor leads to increased PDGF-stimulated chemotaxis but decreased mitogenesis. EMBO J. 1996, 15, 5299-5313.
33. Caldwell, A. G. 9-Substituted acridines. Brit. Patent 997,036; June 30, 1965; Chem. Abstr. 1966, 64, 740c.
34. Kahana, N.; Arad-Yellin, R.; Warshawsky, A.A conceptual approach to the synthesis of bifunctional EDTA analogues: EDTA-extended polyamides. J. Org. Chem. 1994, 59, 4832-4837.
35. Krapcho, A. P.; Maresch, M. J.; Lunn, J. Mono-(BOC)-protected diamines [BOC = tert-butoxycarbonyl]. Synthesis of tert-butyl N-alkyl-N-(2-aminoethyl)carbamates and tert-butyl N-[2-(alkyl-amino)ethyl]carbamates. Synth. Commun. 1993, 23, 2443-2449.
36. Buchdunger, E.; Zimmermann, J.; Mett, H.; Meyer, T.; Muller, M.; Druker, B. J.; Lydon, N. B. Inhibition of the abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996, 56, 100-104.
37. Beckmann, M. P.; Betsholtz, C.; Heldin, C. H.; Westermark, B.; Di Marco, E.; Di Fiore, P. P.; Robbins, K. C.; Aaronson, S. A. Comparison of biological properties and transforming potential of human PDGF-A and PDGF-B chains. Science 1988, 241, 1346-1349.
38. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112.
39. Klohs, W. D.; Steinkampf, R. S. The effect of lysosomotropic agents and secretory inhibitors on anthracycline retention and activity in multiple drug-resistant cells. Mol. Pharmacol. 1988, 34, 180-185.
40. Schabel, F. M., Jr.; Griswold, D. P., Jr.; Laster, W. R., Jr.; Corbett, T. H.; Lloyd, H. H. Quantitative evaluation of anticancer agent activity in experimental animals. Pharmacol. Ther. 1977, 1, 411-435.
41. Leopold, W. R.; Nelson, J. M.; Plowman, J.; Jackson, R. C. Anthrapyrazoles, a new class of intercalating agents with high-level, broad-spectrum activity against murine tumors. Cancer Res. 1985, 45, 5532-5539.
42. Elliott, W. L.; Howard, C. T.; Dykes, D. J.; Leopold, W. R. Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice. Cancer Res. 1989, 49, 5586-5590.
43. Elliott, W. L.; Roberts, B. J.; Howard, C. T.; Leopold III, W. R. Chemotherapy with CI-973 ([SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato (2-)] (2-methyl-1,4-butanediamine-N,N′) platinum, NK121) in combination with standard agents against murine tumors in vivo. Cancer Res. 1994, 54, 4412-4418.
44. Blankley, C. J.; Bennett, L. R.; Fleming, R. W.; Smith, R. D.; Tessman, D. K.; Kaplan, H. R. Antihypertensive activity of 6-arylpyrido[2,3-d]pyrimidin-7-amine derivatives. 2. 7-Acyl amide analogues. J. Med. Chem. 1983, 26, 403-411.